On May 20, 2026, Japan added three ultra-expensive regenerative medicines to public insurance coverage: Amshepri (world's first iPS cell-derived drug, for Parkinson's), Akugo (stem cells for traumatic brain injury), and Zolgensma Intrathecal (gene therapy for SMA patients aged 2+). Prices range from 55 million yen ($352K) to 167 million yen ($1.06M). We explain why these drugs cost so much, how Japan's high-cost medical expense system shields patients, and whether prices might fall over time.
A Japanese research team led by Gakushuin University has discovered Mitorubin, a plant-derived compound that simultaneously increases mitochondrial quantity and function. The compound improved heart function in aged mice and extended median lifespan by about 40% in obese mice on a high-fat diet — a distinct approach from US longevity biotech, NAD supplements, and senolytics.
A Japanese team led by Prof. Takanori Takebe (Osaka & Science Tokyo) and Dr. Mureo Kasahara (National Center for Child Health and Development) plans the world's first pediatric clinical trial of UTOpiA, a bioartificial liver that perfuses blood through iPS-derived liver organoids. Animal trials showed 90% survival. How it compares with King's College London's HELP trial and Beijing's CiPS-BAL.
Kyoto University's iPS Cell Research Institute (CiRA) has succeeded in producing 'helper T cells'—the conductors of the immune system—from iPS cells without using mouse feeder cells. The breakthrough opens a path beyond the limits of $500K+ CAR-T therapy, especially for patients whose own immune cells are exhausted from chemotherapy. Here's how Japan's progress compares with US efforts at Memorial Sloan Kettering and China's surging T-cell pipeline.
A Tohoku University-UC Irvine team led by Prof. Kei Igarashi has discovered that dopamine in the entorhinal cortex drops to less than one-fifth of normal levels in Alzheimer's mice, driving memory loss. Published in Nature Neuroscience, the finding suggests Levodopa—a Parkinson's drug used for over half a century—could restore memory in Alzheimer's, opening a new path beyond the amyloid-beta hypothesis behind drugs like lecanemab.
Tokushima University researchers led by Prof. Tomohide Saio have unveiled OptoChaperone in JACS, a biohybrid tool that uses light to reversibly switch protein droplets on and off inside living cells. A look at how this Japanese breakthrough could accelerate ALS and Alzheimer's drug discovery, and how it compares with US and European condensate startups like Dewpoint Therapeutics and Nereid.
Panasonic has partnered with Kyoto University's iPS Cell Research Foundation to begin proof-of-concept trials for fully automating iPS cell establishment at Osaka's Nakanoshima Cross. The goal: slash per-patient costs from tens of millions of yen to around 1 million yen. How does Japan's approach compare with US rival Cellino's laser-driven biomanufacturing?
Researchers at Utsunomiya University have provided the world's first direct proof that ceramide deficiency in the skin causes atopic dermatitis. Using transgenic mice, they demonstrated the full disease cascade from barrier breakdown to allergic inflammation — opening doors for ceramide-based therapies and enzyme-targeting treatments for the 200+ million people affected worldwide.
Japan's iCELL BANK launched in April 2026, offering individuals the ability to create and cryopreserve their own iPS cells for future regenerative medicine. Using ID Pharma's Sendai virus vector technology, the service marks a new phase in commercializing the Nobel Prize-winning iPS cell technology for everyday consumers.
Nobel laureate Shinya Yamanaka explained iPS Cell 2.0 on NTV's Bankisha. From next-gen stem cell tech overcoming current limitations to universal blood platelets that bypass blood-type matching, plus Japan's historic first-ever iPSC drug approvals in 2026 — a comprehensive look at where iPS cells stand 20 years after their discovery.
Fujitsu and Osaka University developed STAR Architecture ver. 3 and molecular model optimization to cut quantum computing resources to between 1/15 and 1/80 of conventional FTQC needs. Calculations for drug-critical Cytochrome P450 fall from 740,000 to 40,000 qubits and complete in 9 days. Comparison with IBM, Google, and IonQ's quantum drug discovery efforts included.
